New expectations make the Lundbeck share plummet
The Danish pharma-group Lundbeck has lowered expectations for its operating result in coming years, as the company will invest in a number of new product launches. Read on to see which products will eat away at profits.
by Kresten Morten Munksgaard
Denmark’s second-largest pharmaceutical company, Lundbeck, has lowered its expectations for operating results in 2013 and 2014 significantly, the company announces in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Sydbank: A positive signal
For abonnenter
